# Metabolic-Associated Steatotic Liver Disease: From Molecular Mechanisms to Novel Therapies

## TL;DR

This review explores the molecular causes and treatment options for metabolic-associated steatotic liver disease, a major global health issue.

## Contribution

The paper provides a comprehensive overview of molecular mechanisms and clinical trials for MASLD.

## Key findings

- MASLD is the leading reason for liver transplants globally.
- Few effective pharmacological treatments for MASLD are currently available.
- The paper summarizes past, current, and future clinical trials for MASLD therapies.

## Abstract

Metabolic-associated steatotic liver disease (MASLD) is a burgeoning worldwide burden and is currently the leading indication for a liver transplant. Despite the growing burden of disease, there are few pharmacological treatments available. The underlying molecular mechanisms of the development of MASLD are still being elucidated. In this review, we will summarize the known molecular mechanisms in the development of MASLD along with past, current, and future pharmacologic clinical trials.